What is Athersys Inc?
Athersys Inc. is a biotechnology firm dedicated to the discovery and development of therapeutic product candidates aimed at enhancing human life. The company's flagship product, MultiStem®, is a patented, adult-derived stem cell therapy designed for indications across neurological, inflammatory, immune, cardiovascular, and critical care fields. With several ongoing clinical trials, Athersys is advancing its potential regenerative medicine product toward commercialization through strategic partnerships and a robust network of collaborations.
How much funding has Athersys Inc raised?
Athersys Inc has raised a total of $264.5M across 9 funding rounds:
Share Placement
$9M
Debt
$25M
Stock Offering
$23M
Debt
$100M
Share Placement
$7M
Share Placement
$12M
Other Financing Round
$10.4M
Share Placement (2012): $9M supported by Undisclosed
Debt (2013): $25M featuring Aspire Capital
Stock Issuance/Offering (2017): $23M backed by Undisclosed
Debt (2018): $100M with participation from Aspire Capital
Share Placement (2020): $7M led by Healios
Share Placement (2022): $12M, investors not publicly disclosed
Other Financing Round (2023): $10.4M, investors not publicly disclosed
Key Investors in Athersys Inc
Aspire Capital
Aspire Capital is a venture capital firm that focuses on building long-term, win-win relationships with publicly traded companies, aligning incentives to support their success and growth through reliable and reasonable investment.
Pappas Ventures
Pappas Ventures is a venture capital firm specializing in advancing biopharma, biotech, and medical technologies, with a focus on innovative life science products and technologies aimed at improving patient outcomes.
Radius Ventures
Radius Ventures was a venture capital firm focused on building innovative companies in the health and life sciences sectors, known for its disciplined, domain-driven investment approach that transformed patient care and advanced medical innovation.
What's next for Athersys Inc?
The recent major strategic investment signals a pivotal phase for Athersys Inc., likely enabling the company to accelerate its clinical trial progress and scale up manufacturing capabilities for its MultiStem® cell therapy. This capital infusion is expected to bolster its efforts in bringing innovative regenerative medicine solutions to market, potentially marking a transition from development to commercialization. The company's focus on critical care indications suggests a strategic move towards addressing significant unmet medical needs.
See full Athersys Inc company page
